The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges - GBI Research Reports

The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges

The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges - GBI Research Reports
The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges
Published Mar 25, 2010
141 pages — Published Mar 25, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

SummaryGBI Research has released its research - 'The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges'. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global pain management therapeutics market. The report analyzes the markets for pain management in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes:- Annualized market data for the pain management market from 2001 to 2009, forecast forward to 2016.- Analysis of the leading therapeutic segments, including neuropathic pain, osteoarthritis, cancer pain, migraine and fibromyalgia.- Analysis of the pain management market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.- Market characterization of the pain management market including market size, the annual cost of therapy, sales volume and treatment usage patterns. - Key drivers and barriers that have a significant impact on the market. - Coverage of pipeline molecules in the various phases of drug development. - Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson, Novartis AG, Merck & Co Inc., and Cephalon, Inc.- Key M&A activities that have taken place in 2009 and the licensing agreements in the 2008-2009 global pain management market.Reasons to buyThe report will enhance your decision making capability. It will allow you to - Align product portfolio to the markets with high growth potential - Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth - Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety - Develop key strategic initiatives by understanding key focus areas of leading companies - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

  
Source:
Document ID
GBIHC026MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents49
1.1 List of Tables73
1.2 List of Figures103
2 Global Pain Management Therapeutics Market: Introduction131
2.1 GBI Research Report Guidance131
3 Global Pain Management Therapeutics Market: Market Overview1412
3.1 Introduction141
3.2 Revenue Forecast for the Global Pain Management Therapeutics Market151
3.2.1 Sales Value151
3.2.2 Patient Volume161
3.2.3 Annual Cost of Therapy171
Treatment Usage Patterns181
3.2.4.1 Diseased Population191
3.2.4.2 Treatment Seeking Population201
3.2.4.3 Diagnosed Population211
3.2.4.4 Prescription Population221
3.2.5 Generics Share in the Global Pain Management Therapeutics Market231
3.2.6 Sales of Leading Drugs241
3.3 Pain Management Therapeutics Market Drivers251
3.3.1 Increase in Diagnosed and Prescription Population251
Global Pain Management Therapeutics Market: Therapeutic Landscape2649
4.1 Fibromyalgia Market261
4.1.1 Introduction261
4.1.2 Sales Value262
4.1.3 Patient Volume281
4.1.4 Annual Cost of Therapy291
4.1.5 Treatment Usage Patterns302
4.1.5.1 Diseased Population321
4.1.5.2 Treatment Seeking Population331
4.1.5.3 Diagnosed Population341
4.1.5.4 Prescription Population 351
Drivers for Fibromyalgia Pain Market351
4.1.6.1 Ageing Population Will Drive Prevalence 351
4.1.6.2 Improvement in Awareness and Resultant Diagnosis Levels Will Drive the Market361
4.1.6.3 Substantial Unmet Need increases the Market Potential361
4.1.7 Restraints for Fibromyalgia Pain Market361
4.1.7.1 Limitations in the Efficacy of Existing Drugs Leads Can Potentially Lead to Low Prescription361
4.1.7.2 Inadequate Knowledge of Disease Progression Hinder the Development of Drugs With Better Efficacy361
4.1.8 Unmet Needs361
4.2 Neuropathic Pain Market361
4.2.1 Introduction361
4.2.2 Sales Value371
4.2.3 Patient Volume381
4.2.4 Annual Cost of Therapy391
4.2.5 Treatment Usage Patterns402
4.2.5.1 Diseased Population421
4.2.5.2 Treatment Seeking Population431
4.2.5.3 Diagnosed Population441
4.2.5.4 Prescription Population 451
4.2.6 Drivers for Neuropathic Pain Market451
4.2.6.1 Ageing Population and Increasing Prevalence of Diabetes and HIV Will Drive The Prevalence of Neuropathic Pain Which is Known to Be High in Aged Population451
4.2.6.2 A more Active Treatment Seeking Behavior to Drive Increase in Patient Volume451
4.2.7 Restraints for Neuropathic Pain Market461
4.2.7.1 Non Availability of Accurate Tools that Aid Diagnosis Is a Hindrance for Market Growth461
4.2.8 Unmet Need461
4.3 Migraine Market461
4.3.1 Introduction461
4.3.2 Sales Value471
4.3.3 Patient Volume481
4.3.4 Annual Cost of Therapy491
4.3.5 Treatment Usage Patterns502
4.3.5.1 Diseased Population521
4.3.5.2 Treatment Seeking Population531
4.3.5.3 Diagnosed Population541
4.3.5.4 Prescription Population 551
4.3.6 Drivers for Migraine Market551
4.3.6.1 The Increasing Awareness Will Result In Increasing Prescription Rate551
4.3.7 Restraints for Migraine Market551
4.3.7.1 Low Treatment Seeking Behavior and Diagnosis Rate Restrain the Growth in Prescription Population551
4.3.7.2 Falling Prices of Migraine Treatment Will Restrain the Market by Off setting the impact of increasing volume 561
4.3.8 Unmet Need561
4.4 Cancer Pain Market561
4.4.1 Introduction561
4.4.2 Sales Value562
4.4.3 Patient Volume581
4.4.4 Annual Cost of Therapy591
4.4.5 Treatment Usage Patterns601
4.4.5.1 Diseased Population611
4.4.5.2 Treatment Seeking Population621
4.4.5.3 Diagnosed Population631
4.4.5.4 Prescription Population 641
4.4.6 Drivers for Cancer Pain Market641
4.4.6.1 Increasing Treatment Seeking, Diagnosis and Prescription Rate Will Drive the Market641
4.4.6.2 New Modes of Delivery Will Help in Better Management of the Pain for a Longer Duration651
4.4.7 Restraints for Cancer Pain Market651
4.4.7.1 Concerns Over the Risks of Addiction Related to Drug Therapy Will Affect the Prescription Rate651
4.4.8 Unmet Need651
4.5 Osteoarthritis Pain Market651
4.5.1 Introduction651
4.5.2 Sales Value661
4.5.3 Patient Volume671
4.5.4 Annual Cost of Therapy681
4.5.5 Treatment Usage Patterns691
4.5.5.1 Diseased Population701
4.5.5.2 Treatment Seeking Population711
4.5.5.3 Diagnosed Population721
4.5.5.4 Prescription Population 731
4.5.6 Drivers for Osteoarthritis Pain Market731
4.5.6.1 An Aging Population731
4.5.6.2 Increase in the Obese Population Which is Associated with a Higher Risk of Osteoarthritis Will Drive Volume731
4.5.7 Restraints for Osteoarthritis Pain Market741
4.5.7.1 Low Treatment Seeking and Diagnosis Rate741
4.5.8 Unmet Need741
5 Global Pain Management Therapeutics Market: Geographical Landscape7527
5.1 Geographical Break-up752
5.2 The US771
5.2.1 Sales Value771
5.2.2 Patient Volume781
5.2.3 Annual Cost of Therapy791
5.2.4 Treatment Usage Patterns801
5.2.4.1 Diseased Population811
5.2.4.2 Treatment Seeking Population821
5.2.4.3 Diagnosed Population831
5.2.4.4 Prescription Population 841
5.3 Top Five Countries in Europe851
5.3.1 Sales Value851
5.3.2 Patient Volume861
5.3.3 Annual Cost of Therapy871
5.3.4 Treatment Usage Patterns881
5.3.4.1 Diseased Population891
5.3.4.2 Treatment Seeking Population901
5.3.4.3 Diagnosed Population911
5.3.4.4 Prescription Population 921
5.4 Japan931
5.4.1 Sales Value931
5.4.2 Patient Volume941
5.4.3 Annual Cost of Therapy951
5.4.4 Treatment Usage Patterns962
5.4.4.1 Diseased Population981
5.4.4.2 Treatment Seeking Population991
5.4.4.3 Diagnosed Population1001
5.4.4.4 Prescription Population 1011
6 Global Pain Management Therapeutics Market: Pipeline Analysis10210
6.1 Introduction1021
6.1.1 Research and Development Pipeline Fibromyalgia1031
6.1.2 Research and Development Pipeline Neuropathic Pain1041
6.1.3 Research and Development Pipeline Migraine1051
6.1.4 Research and Development Pipeline Cancer Pain1061
6.1.5 Research and Development Pipeline Osteoarthritis Pain1061
6.2 Profiles of Key Late-Stage Drugs in the Pain Management Market1071
6.2.1 Droxopida1071
6.2.1.1 Introduction1071
6.2.1.2 Clinical Trial Management1071
6.2.2 Xyrem1071
6.2.2.1 Introduction1071
6.2.2.2 Clinical Trial Management1071
6.2.3 Vimpat (lacosamide)1071
6.2.3.1 Introduction1071
6.2.3.2 Clinical Trial Management1081
6.2.4 Qutenza (capsaicin 8%)1081
6.2.4.1 Introduction1081
6.2.4.2 Clinical Trial Management1091
6.2.5 Botox1091
6.2.5.1 Introduction1091
6.2.6 Tezampanel1101
6.2.6.1 Introduction1101
6.2.6.2 Clinical Trial Management1101
6.2.7 Nasalfent1101
6.2.7.1 Introduction1101
6.2.7.2 Clinical Trial Management1101
6.2.8 PF-4383119 (Tanezumab)1111
6.2.8.1 Introduction1111
6.2.8.2 Clinical Study Details1111
7 Global Pain Management Therapeutics Market: Competitive Landscape11213
7.1 Market Share Analysis1121
7.2 Competitive Profiling1122
7.2.1 Pfizer, Inc.1141
7.2.1.1 Product Portfolio1141
7.2.1.2 Product Pipeline1151
7.2.2 Eli Lilly and Company1151
7.2.2.1 Product Portfolio1161
7.2.2.2 Product Pipeline1161
7.2.3 Johnson &Johnson1171
7.2.3.1 Product Portfolio1181
7.2.3.2 Product Pipeline1191
7.2.4 Endo Pharmaceuticals1191
7.2.4.1 Product portfolio1201
7.2.4.2 Product Pipeline1201
7.2.5 Novartis AG1201
7.2.5.1 Product Portfolio1211
7.2.5.2 Product Pipeline1221
7.2.6 Merck &Co Inc1221
7.2.6.1 Product Portfolio1231
7.2.6.2 Product Pipeline1231
7.2.7 Cephalon, Inc.1231
7.2.7.1 Product Portfolio 1241
7.2.7.2 Product Pipeline 1241
8 Global Pain Management Therapeutics Market: Strategic Consolidations12511
8.1 Overview1252
8.1.1 Sanofi-Aventis Acquired 100% outstanding shares of Chattem, Inc in December 20091271
8.1.2 Dainippon Sumitomo Pharma Acquired Sepracor, Inc. in October 20091271
8.1.3 Raptor Pharmaceuticals and TorreyPines Therapeutics Merged in August 20091271
8.1.4 Alexza Pharmaceuticals Acquired Symphony Allegro in June 20091271
8.1.5 Anesiva and Arcion Therapeutics Merge in May 20091271
8.1.6 Mylan Laboratories Acquired Matrix Laboratories Limited in March 20091281
8.2 R&D Licensing Agreements 1281
8.2.1 Deals by Indication1281
8.2.2 Deals by Phase1291
8.2.3 Deals by Geography1301
8.2.4 Deals by Value ($)1311
8.2.5 Preclinical and Discovery1311
8.2.5.1 PL37 1311
8.2.5.2 PRS-6390581311
8.2.5.3 Osteoarthritis Program1321
8.2.6 Phase I1321
8.2.6.1 AGN-2093231321
8.2.6.2 SI-0004131321
8.2.7 Phase II1321
8.2.7.1 AMG 1081331
8.2.8 Phase III1331
8.2.8.1 Rapinyl1331
8.2.8.2 HFT-290 (Fentanyl)1331
8.2.8.3 Prochymal 1331
8.2.8.4 AD 9231331
8.2.8.5 Civanex1341
8.2.9 Approved and Regulatory Filing1341
8.2.9.1 Orthovisc 1341
8.2.9.2 Onsolis 1341
8.2.9.3 Glucomed 1351
8.2.9.4 Voltaren 1351
8.2.9.5 Sumavel DosePro 1351
8.2.9.6 Qutenza 1351
8.2.9.7 Rapinyl1351
8.2.9.8 Lyrica1351
9 Global Pain Management Therapeutics Market: Appendix1366
9.1 Market Definitions1361
9.2 Abbreviations1361
9.3 Research Methodology1374
9.3.1 Coverage 1371
9.3.2 Secondary Research1381
9.3.3 Primary Research1381
9.3.4 Forecasts1381
9.3.4.1 Epidemiology-based Forecasting1382
9.3.5 Expert Panel Validation1401
9.4 Contact Us1411
9.5 Disclaimer1411
9.6 Sources1411

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges" Mar 25, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Pain-Management-Therapeutics-Analysis-and-Market-Forecasts-to-2016-Increasing-Generic-Competition-Creates-Challenges-2115-36>
  
APA:
GBI Research Reports. (2010). The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges Mar 25, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Pain-Management-Therapeutics-Analysis-and-Market-Forecasts-to-2016-Increasing-Generic-Competition-Creates-Challenges-2115-36>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.